comparemela.com

Latest Breaking News On - Efficacy results - Page 13 : comparemela.com

Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ®) Improved Clinical and Endoscopic Outcomes in Patients with Crohn s Disease

/PRNewswire/ AbbVie (NYSE: ABBV) today announced positive top-line results from U-EXCEL, a Phase 3 induction study, showing upadacitinib (45 mg once daily).

United statesMichael severinoGastroenterol hepatolAccess economics ptyDrug administrationExchange commissionEu european medicines agencyAbbvie incAbbvie deutschland gmbh coCrohn colitis foundation of americaCrohn disease programDisease activity indexEfficacy resultsMedicines agencyUpadacitinib phaseImportant safety

AVEO Oncology Presents Three Posters for

First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC Two.

United statesMichael baileyUniversity of florida health cancer centerPharma united kingdomDrug administrationEuropean unionPharmaceuticals incAmerican cancer societyClinical oncology gastrointestinalFlorida health cancer centerChief executive officerSafety data poster titleAdvanced hepatocellular carcinomaEfficacy resultsPreviously untreated patientsProgress poster presentation

ASH 2021 | Ascentage Pharma Releases Long-Term Clinical Data of Olverembatinib (HQP1351) in Oral Presentation Demonstrating Efficacy and Safety

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),.

United statesHong kongQian jiangAscentage pharmaYifan zhaiPrnewswire ascentage pharmaXiaojun huangMajor nationalMd anderson cancer centerAmerican society of hematologyChina national medical products administrationHematology department of peking university people hospitalNational major new drug discoveryDana farber cancer instituteAmerican societyHematology department

Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology Annual Meeting and the 44th San Antonio Breast Cancer Symposium

/PRNewswire/ Ryvu Therapeutics (WSE: RVU) a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address.

United statesSan antonioPrnewswire ryvuPawel przewiezlikowskiAmerican societyMenarini groupWarsaw stock exchangeAnnual meetingAnnual san antonio breast cancer symposiumComplete remissionAntonio breast cancer symposiumChief executive officerEfficacy resultsInitial dose escalationPublication numberDrug candidate

Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) Congress

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United statesUnited kingdomSuber huangJenene thomasAsia pacific vitreoSubers huangHarriet ullmanLavoie health scienceAsia pacific academy of ophthalmologyOutlook therapeutics incCongress onRetina centerRetina societyOutlook therapeutic phaseAsia pacific vitreo retina societyOutlook therapeutics

vimarsana © 2020. All Rights Reserved.